PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients
Abstract IONIS‐FXIRX (BAY2306001) is an antisense oligonucleotide that inhibits the synthesis of coagulation factor XI (FXI) and has been investigated in healthy volunteers and patients with end‐stage renal disease (ESRD). FXI‐LICA (BAY2976217) shares the same RNA sequence as IONIS‐FXIRX but contain...
Guardado en:
Autores principales: | Stefan Willmann, Eleonora Marostica, Nelleke Snelder, Alexander Solms, Markus Jensen, Maximilian Lobmeyer, Anthonie W. A. Lensing, Claudette Bethune, Erin Morgan, Rosie Z. Yu, Yanfeng Wang, Shiangtung W. Jung, Richard Geary, Sanjay Bhanot |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Wiley
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a0f07a9e368749df85e58f6529f928d9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Neutrophils can promote clotting via FXI and impact clot structure via neutrophil extracellular traps in a distinctive manner in vitro
por: Y. Shi, et al.
Publicado: (2021) -
Phospholamban antisense oligonucleotides improve cardiac function in murine cardiomyopathy
por: Niels Grote Beverborg, et al.
Publicado: (2021) -
Tritium labeling of antisense oligonucleotides via different conjugation agents
por: Martin R. Edelmann, et al.
Publicado: (2021) -
Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle
por: James S. Novak, et al.
Publicado: (2017) -
Induction of cryptic pre-mRNA splice-switching by antisense oligonucleotides
por: Kristin A. Ham, et al.
Publicado: (2021)